Patent: 9,789,165
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Summary for Patent: 9,789,165
| Title: | Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists |
| Abstract: | The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. |
| Inventor(s): | Kadereit; Dieter (Frankfurt am Main, DE), Lorenz; Katrin (Frankfurt am Main, DE), Evers; Andreas (Frankfurt am Main, DE), Haack; Torsten (Frankfurt am Main, DE), Wagner; Michael (Frankfurt am Main, DE), Henkel; Bernd (Frankfurt am Main, DE), Lorenz; Martin (Frankfurt am Main, DE), Stengelin; Siegfried (Frankfurt am Main, DE) |
| Assignee: | SANOFI (Paris, FR) |
| Application Number: | 14/569,055 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,789,165
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | 10/28/1982 | ⤷ Sign Up | 2033-12-13 |
| Eli Lilly And Company | HUMULIN R U-500 | insulin human | Injection | 018780 | 12/29/2015 | ⤷ Sign Up | 2033-12-13 |
| Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | 08/06/1998 | ⤷ Sign Up | 2033-12-13 |
| Eli Lilly And Company | HUMULIN R U-500 | insulin human | Injection | 018780 | 03/31/1994 | ⤷ Sign Up | 2033-12-13 |
| Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | 05/25/2018 | ⤷ Sign Up | 2033-12-13 |
| Novo Nordisk Inc. | NOVOLIN R | insulin human | Injection | 019938 | 06/25/1991 | ⤷ Sign Up | 2033-12-13 |
| Novo Nordisk Inc. | NOVOLIN R | insulin human | Injection | 019938 | 06/01/2018 | ⤷ Sign Up | 2033-12-13 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
